CDH1 and prostate cancer: It has been reported that CDH1 expression is notably elevated in prostate cancer cells (PC-3 and DU-145) upon treatment with SIT; the initiation and development of cancer correlate with the decrease in CDH1 expression, and the loss of function of this gene enhances invasive and metastatic capabilities, which in turn expedites tumor progression (63).